Nearly 40 stakeholder groups across the health care community have agreed to work collaboratively to advance biosimilar products, thereby increasing access to biological medicines.
The group includes patient representatives, physicians, pharmacists, patient advocacy organization representatives, payer representatives, government regulatory agency representatives and manufacturer representatives, and was spurred by workshops convened by the Biosimilars Forum, a nonprofit organization whose mission is to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines and improving health care. The new group will work together to break down barriers to educate stakeholders about the benefits of biosimilars in improving affordability and access to treatment and care for patient and provider communities.
“The Biosimilars Forum is looking forward to facilitating and collaborating with diverse voices across the patient, physician, advocacy, provider and government space through an ongoing dialogue supporting the growth of biosimilars throughout the U.S. health care system,” said Juliana M. Reed, President of the Biosimilars Form. “Through bringing diverse viewpoints to the table and emerging with a singular voice calling for greater use of biosimilars, our shared goal is to benefit patients in need across the United States.”
In April, the Biosimilars Forum convened the second of a series of conversations inviting stakeholder groups to discuss the biosimilars landscape. These conversations are intended to result in meaningful action in the future that will contribute to a more vibrant biosimilars market emerging in the United States.
Stakeholder Workshop Steering Committee
About The Biosimilars Forum
The Biosimilars Forum is a nonprofit organization whose mission is to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines, and improving health care. The founding members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios.
For more information, visit BiosimilarsForum.org.
SOURCE: The Biosimilars Forum